VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.
Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, ...
HumminGuru’s EZ Vinyl Record Washer targets Spin-Clean with a more refined manual cleaner—effective, easy to use, and price ...
inews.co.uk on MSN
Think you know about good and bad cholesterol? Read this first
The issue of cholesterol is a lot more complicated than most people think – there are as many as eight different blood tests ...
Baltimore might just be America’s best-kept real estate secret, hiding in plain sight along the sparkling Chesapeake Bay. While coastal property prices skyrocket nationwide, this historic harbor city ...
The issuance further underscores BIRET’s continued commitment to embedding sustainability into its business strategy ...
Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback